Prospective analysis of bleeding events in left ventricular assist device patients

Abstract

Background:

Bleeding is a major cause of morbidity in patients with continuous flow left ventricular assist devices (LVADs). We sought to identify clinical predictors of bleeding within the first year of LVAD implantation.

Methods:

A prospective study was performed on 30 patients with HeartMate II implantation at the University of Rochester Medical Center, Rochester, New York, United States. Blood was collected within 1 week before implantation, and at 1, 3, and 30 ± 10 days after implantation. Blood samples were analyzed for prothrombin time (PT), international normalized ratio (INR), von Willebrand factor (vWF) activity, vWF antigen, vWF multimers, collagen binding assay, factor VIII, and epinephrine closure time. The first bleeding event within 1 year of implantation was recorded.

Results:

There were 17 (57%) patients with a bleeding event. The cumulative incidence of bleeding was 50% at 304 days. Age at the time of LVAD implantation was associated with higher risk of bleeding (hazard ratio (HR) = 1.05, 95% confidence interval (CI) = 1.01–1.10, p = 0.013). Higher baseline INR was also associated with increased risk of bleeding after adjusting for age at the time of implant (HR = 6.58, 95% CI = 1.21–35.70, p = 0.028). The bleeders and non-bleeders had similar hemostatic markers at all four time points. Prior to LVAD, mean epinephrine closure time was similar between bleeders and non-bleeders. However, post LVAD measurement of epinephrine, closure time was frequently limited by platelet clumping.

Conclusion:

Older age and baseline INR are associated with higher risk of bleeding in LVAD patients. Platelet clumping may suggest underlying platelet dysfunction and associated high risk of bleeding

Keywords

Bleeding von Willebrand factor left ventricular assist device

Get full access to this article

View all access options for this article.

References

Pagani

Miller

Russell

et al . Extended mechanical circulatory support with a continuous-flow rotary left ventricular assist device. J Am Coll Cardiol 2009; 54: 312–321.

Starling

Naka

Boyle

et al . Results of the post-U.S. Food and Drug Administration-approval study with a continuous flow left ventricular assist device as a bridge to heart transplantation: a prospective study using the INTERMACS (Interagency Registry for Mechanically Assisted Circulatory Support). J Am Coll Cardiol 2011; 57: 1890–1898.

Slaughter

Rogers

Milano

et al . Advanced heart failure treated with continuous-flow left ventricular assist device. N Engl J Med 2009; 361: 2241–2251.

Lahpor

Khaghani

Hetzer

et al . European results with a continuous-flow ventricular assist device for advanced heart-failure patients. Eur J Cardiothorac Surg 2010; 37: 357–361.

Demirozu

Radovancevic

Hochman

et al . Arteriovenous malformation and gastrointestinal bleeding in patients with the HeartMate II left ventricular assist device. J Heart Lung Transplant 2011; 30: 849–853.

Stern

Kazam

Edwards

et al . Increased incidence of gastrointestinal bleeding following implantation of the HeartMate II LVAD. J Card Surg 2010; 25: 352–356.

Hasin

Marmor

Kremers

et al . Readmissions after implantation of axial flow left ventricular assist device. J Am Coll Cardiol 2013; 61: 153–163.

Meyer

Malehsa

Budde

et al . Acquired von Willebrand syndrome in patients with a centrifugal or axial continuous flow left ventricular assist device. JACC Heart Fail 2014; 2: 141–145.

Crow

Chen

Milano

et al . Acquired von Willebrand syndrome in continuous-flow ventricular assist device recipients. Ann Thorac Surg 2010; 90: 1263–1269.

10.

Geisen

Heilmann

Beyersdorf

et al . Non-surgical bleeding in patients with ventricular assist devices could be explained by acquired von Willebrand disease. Eur J Cardiothorac Surg 2008; 33: 679–684.

11.

Boyle

Jorde

Sun

et al . Pre-operative risk factors of bleeding and stroke during left ventricular assist device support: an analysis of more than 900 HeartMate II outpatients. J Am Coll Cardiol 2014; 63: 880–888.

12.

Igawa

Oka

Tanaka

et al . Major predictors and management of small-bowel angioectasia. BMC Gastroenterol 2015; 15: 108.

13.

Meyer

Malehsa

Bara

et al . Acquired von Willebrand syndrome in patients with an axial flow left ventricular assist device. Circ Heart Fail 2010; 3: 675–681.

14.

Nascimbene

Neelamegham

Frazier

et al . Acquired von Willebrand syndrome associated with left ventricular assist device. Blood 2016; 127: 3133–3141.

15.

Vischer

. von Willebrand factor, endothelial dysfunction, and cardiovascular disease. J Thromb Haemost 2006; 4: 1186–1193.

16.

Holmberg

Nilsson

Borge

et al . Platelet aggregation induced by 1-desamino-8-D-arginine vasopressin (DDAVP) in type IIB von Willebrand’s disease. N Engl J Med 1983; 309: 816–821.

17.

Turner

Moake

Kamat

et al . Comparative real-time effects on platelet adhesion and aggregation under flowing conditions of in vivo aspirin, heparin, and monoclonal antibody fragment against glycoprotein IIb-IIIa. Circulation 1995; 91: 1354–1362.

18.

Turner

Moake

McIntire

. Blockade of adenosine diphosphate receptors P2Y(12) and P2Y(1) is required to inhibit platelet aggregation in whole blood under flow. Blood 2001; 98: 3340–3345.

19.

Moake

Turner

Stathopoulos

et al . Shear-induced platelet aggregation can be mediated by vWF released from platelets, as well as by exogenous large or unusually large vWF multimers, requires adenosine diphosphate, and is resistant to aspirin. Blood 1988; 71: 1366–1374.

20.

Shimomura

Nagata

Shimbo

et al . A new predictive model for acute gastrointestinal bleeding in patients taking oral anticoagulants. J Gastroenterol Hepatol 2018; 33: 164–171.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.25 MB